Publication

Medicaments for the treatment of vasoconstriction related diseases or disorders

Henning, R. H., Euverink, G. J. W., Krenning, G. & van der Graaf, A. C., 28-Feb-2019, Patent No. WO2019038361, 23-Feb-2018, Priority date 25-Aug-2017

Research output: PatentProfessional

APA

Henning, R. H., Euverink, G. J. W., Krenning, G., & van der Graaf, A. C. (2019). Medicaments for the treatment of vasoconstriction related diseases or disorders. (Patent No. WO2019038361).

Author

Henning, Robert Henk (Inventor) ; Euverink, Gerrit Jan Willem (Inventor) ; Krenning, Guido (Inventor) ; van der Graaf, Adrianus Cornelis (Inventor). / Medicaments for the treatment of vasoconstriction related diseases or disorders. Patent No.: WO2019038361. Feb 23, 2018.

Harvard

Henning, RH, Euverink, GJW, Krenning, G & van der Graaf, AC Feb. 23 2018, Medicaments for the treatment of vasoconstriction related diseases or disorders, Patent No. WO2019038361.

Standard

Medicaments for the treatment of vasoconstriction related diseases or disorders. / Henning, Robert Henk (Inventor); Euverink, Gerrit Jan Willem (Inventor); Krenning, Guido (Inventor); van der Graaf, Adrianus Cornelis (Inventor).

Patent No.: WO2019038361. Feb 23, 2018.

Research output: PatentProfessional

Vancouver

Henning RH, Euverink GJW, Krenning G, van der Graaf AC, inventors. Medicaments for the treatment of vasoconstriction related diseases or disorders. WO2019038361. 2019 Feb 28.


BibTeX

@misc{45ef45079c92489b88f912a7745cde3b,
title = "Medicaments for the treatment of vasoconstriction related diseases or disorders",
abstract = "The present invention relates to medicaments for use in the prophylaxis or treatment of vasoconstriction related disorders or conditions. Specifically, the present invention relates to (2R) enantiomeric form of a 6-chromanol derivative for use in the prophylactic or treatment of vasoconstriction related disorders or conditions. A preferred 6-chromanol derivative is (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-l-yl)methanone; N-(benzyl)-6-hydroxy- 2,5,7, 8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2- carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6- hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts thereof.",
author = "Henning, {Robert Henk} and Euverink, {Gerrit Jan Willem} and Guido Krenning and {van der Graaf}, {Adrianus Cornelis}",
year = "2019",
month = "2",
day = "28",
language = "English",
type = "Patent",
note = "WO2019038361",

}

RIS

TY - PAT

T1 - Medicaments for the treatment of vasoconstriction related diseases or disorders

AU - Henning, Robert Henk

AU - Euverink, Gerrit Jan Willem

AU - Krenning, Guido

AU - van der Graaf, Adrianus Cornelis

PY - 2019/2/28

Y1 - 2019/2/28

N2 - The present invention relates to medicaments for use in the prophylaxis or treatment of vasoconstriction related disorders or conditions. Specifically, the present invention relates to (2R) enantiomeric form of a 6-chromanol derivative for use in the prophylactic or treatment of vasoconstriction related disorders or conditions. A preferred 6-chromanol derivative is (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-l-yl)methanone; N-(benzyl)-6-hydroxy- 2,5,7, 8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2- carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6- hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts thereof.

AB - The present invention relates to medicaments for use in the prophylaxis or treatment of vasoconstriction related disorders or conditions. Specifically, the present invention relates to (2R) enantiomeric form of a 6-chromanol derivative for use in the prophylactic or treatment of vasoconstriction related disorders or conditions. A preferred 6-chromanol derivative is (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-l-yl)methanone; N-(benzyl)-6-hydroxy- 2,5,7, 8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2- carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6- hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts thereof.

M3 - Patent

M1 - WO2019038361

Y2 - 2018/02/23

ER -

ID: 82488689